ASMA MOSBAH

Dr. ASMA MOSBAH


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2023 in Plants
Verified
Journal Article
Open access
PDF file
AMASMA MOSBAH
ASMA MOSBAH
HKHanane Khither
Hanane Khither
CMCamélia Mosbah
Camélia Mosbah
ASAbdelkader Slimani
Abdelkader Slimani
AMAbdelkader MAHROUK
Abdelkader MAHROUK
Gema NietoGema Nieto
Gema Nieto
Background: many previous studies have demonstrated the therapeutic potential of N. sativa total oil fractions, neutral lipids (NLs), glycolipids (GLs), phospholipids (PLs), and unsaponifiable (IS) in asthma patients. We therefore tested its effect on airway smooth muscle (ASM) cells by observing its ability to regulate the production of glucocorticoid (GC)-insensitive chemokines in cells treated with TNF-α/IFN-γ, and its antioxidative and reactive oxygen species (ROS) scavenging properties. Materials and methods: the cytotoxicity of N. sativa oil fractions was assessed using an MTT assay. ASM cells were treated with TNF-α/IFN-γ for 24 h in the presence of different concentrations of N. sativa oil fractions. An ELISA assay was used to determine the effect of N. sativa oil fractions on chemokine production (CCL5, CXCL-10, and CXCL-8). The scavenging effect of N. sativa oil fractions was evaluated on three reactive oxygen species (ROS), O2•−, OH•, and H2O2. Results: our results show that different N. sativa oil fractions used at 25 and 50 µg/mL did not affect cell viability. All fractions of N. sativa oil inhibited chemokines in a concentration-dependent manner. Interestingly, the total oil fraction showed the most significant effect of chemokine inhibition, and had the highest percentage of ROS scavenging effect. Conclusion: these results suggest that N. sativa oil modulates the proinflammatory actions of human ASM cells by inhibiting the production of GC-insensitive chemokines.

9 April 2026 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
MBMohamed Yahia Zeriab Badaoui
Mohamed Yahia Zeriab Badaoui
AMASMA MOSBAH
ASMA MOSBAH
EMEl Hassen Mokrani
El Hassen Mokrani
KRKhellaf Rebbas
Khellaf Rebbas
AMAbdelkader MAHROUK
Abdelkader MAHROUK
SASalah Akkal
Salah Akkal

1 January 2024 in Turkish Computational and Theoretical Chemistry
Verified
Journal Article
Open access
PDF file
HBHanane Boucherıt
Hanane Boucherıt
AMAmina Merzoug
Amina Merzoug
IBIlham Boulhıssa
Ilham Boulhıssa
AMASMA MOSBAH
ASMA MOSBAH
ABAbderrahmane Benseguenı
Abderrahmane Benseguenı
The discovery of the importance of angiogenesis in the mechanisms of tumor growth has empowered the improvement of new particles that are utilized in the therapy of various cancers. The goal of this research was to identify novel compounds functioning as potent VEGFR2 inhibitors in silico. It is an interesting therapeutic target for developing new anti-angiogenic drugs. In this work, molecular simulation studies of enzyme inhibition was carried out by structure-based virtual screening with FlexX program of VEGFR2. This approach makes it possible to model the interactions between a protein and thousands of small chemical compounds. A collection of 6,000 compounds originating from the ZINC chemical library, were tested against the active site of VEGFR2. The ADME-Tox characteristics and molecular dynamics simulation of the potential compounds were also examined. At the end of this screening, the compounds ZINC01534124 and ZINC00588595 appear as new inhibitors theoretically more active towards VEGFR2. Again, these inhibitors have shown significant binding energy by interacting with important residues in the active site. Furthermore, the in silico prediction of a similar drug positively informs us about the ADME-Tox properties of these new compounds. Finally, the stable binding of VEGFR2 with ZINC01534124 and ZINC00588595 is shown using 100 ns molecular dynamics simulations. These findings point to the chemicals ZINC01534124 and ZINC00588595 as potential candidates for VEGFR2 inhibitor research. They might also act as a starting point for further chemical modifications in order to produce therapeutically relevant anti-angiogenic medications.

31 December 2022 in Journal of Herbmed Pharmacology
Verified
Journal Article
Open access
PDF file
AMASMA MOSBAH
ASMA MOSBAH
HKHanane Khither
Hanane Khither
MCMosbah Camélia
Mosbah Camélia
SASlimani Abdelkader
Slimani Abdelkader
AMAbdelkader MAHROUK
Abdelkader MAHROUK
MZMaameri Zaineb
Maameri Zaineb
Introduction: Nigella sativa L. is a widely used medicinal plant throughout the world. The low toxic effects and low price of this plant make it an excellent treatment choice for many diseases. The present study aims to investigate the hepatoprotective effect of N. sativa L. total oil (TO) and its neutral lipid fraction (NLF) via the estimation of circulating xanthine oxidoreductase (XOR) level and anti-XOR antibodies titer. Methods: Antiradical activities of TO and NLF, in vitro, were carried out using three reactive oxygen species (ROS), superoxide anion, hydroxyl radical, and hydrogen peroxide. In vivo study was conducted to determine the possible protective effects of TO and NLF against ethanol-induced hepatotoxicity in rats feeding Lieber-DeCarli liquid diet in both sera and liver homogenate. Before conducting the hepatoprotective effects, we assessed the toxicity of our extracts using the same animal model. The administrated doses of 400 mg/kg for TO and 300 mg/kg for NLF showed no toxic effects. Results: ELISA assay indicated a significant increase (P<0.001) in the level of XOR and the titer of anti-XOR antibodies in rats treated with ethanol compared to the control group. After treatment with TO and NLF, the titer of anti-XOR antibodies and the level of XOR decreased significantly compared to the control group. Conclusion: XOR plays an important role in alcohol liver pathologies as a major source of free radicals. In addition, TO and NLF have significant potential as liver protective agents and might be utilized as new antioxidant therapeutics.